Dosing: Nemvaleukin (LFIV) Monotherapy and Combination with Pembrolizumab Anticipated Program Milestone:  Preliminary data readout for cohort 3 (monotherapy) expected in 1H2025 and for cohort 4 (combination therapy) in 2H 2025 (subject to patient enrollment) >> Learn more about Nemvaleukin Alfa >> Visit the ARTISTRY-6 study website

Dosing: Nemvaleukin (IV) Monotherapy (Potentially Registrational) Anticipated Program Milestone:  Top-line data readout expected in 1H 2025 >> Learn more about Nemvaleukin Alfa >> Visit the ARTISTRY-6 study website